Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Dimerix Limited
  6. News
  7. Most relevant
    DXB   AU000000DXB7

DIMERIX LIMITED

(DXB)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about DIMERIX LIMITED
01/10Dimerix Doses First Patients in Phase 3 Study of COVID-19 Respiratory Complications Dru..
MT
01/10Dimerix Announces Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India
CI
2021Dimerix Secures Australian Ethics Approval for Phase 3 Study of COVID-19 Drug Candidate..
MT
2021Dimerix Limited Receives Ethics Approval in Australia for Phase 3 Covid-19 Study
CI
2021Dimerix Secures Further Grant Funding for COVID-19 Drug Candidate
MT
2021Dimerix Limited Announces It Has Been Awarded Further AUD 100,000 from the Australian G..
CI
2021Dimerix Limited Advises That 662 Patients Have Now Been Recruited into the Feasibility/..
CI
2021DIMERIX : Notification regarding unquoted securities - DXB
PU
2021DIMERIX : Secures Ethics, Regulatory Approval for Phase 3 Kidney Disease Trial in Australi..
MT
2021Dimerix Limited Announces First Approvals Received for Start of Phase 3 FSGS Trial
CI
2021DIMERIX : Expands Phase 3 Study for COVID-19 Drug to Australia; Shares Rise 4%
MT
2021Dimerix Limited Announces Phase 3 DMX-200 Covid-19 Study Expands into Australia
CI
2021DIMERIX : to Raise $3 Million in Oversubscribed Share Purchase Plan
MT
2021DIMERIX : India's Drug Regulator Approves Dimerix's COVID-19 Drug Clinical Study
MT
2021Dimerix Limited Recommends DMX-200 Clinical Study in COVID-19 Patients
CI
2021DIMERIX : Starts Phase Three Study for Kidney Patients; Shares Jump 8%
MT
2021Dimerix Limited Announces Phase 3 Study in FSGS Kidney Patients Commences
CI
2021DIMERIX : Widens Net Loss in FY21; Shares Surge 43%
MT
2021Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
2021DIMERIX : Extends COVID-19 Study Across Europe
MT
2021Dimerix Limited Advises 167 Patients Have Now Been Recruited into the Feasibility/Phase..
CI
2021DIMERIX : Phase 3 Kidney Disease Study Design Gets Nod from US FDA
MT
2021FDA Confirms Dimerix Limited Phase 3 Study Design in FSGS Kidney Disease
CI
2021Dimerix Receives Innovation Passport and ILAP Designation
CI
2021Dimerix Limited Confirms Phase 3 FSGS Kidney Disease Study Design with EMA
CI
2021Dimerix Limited Confirms Active Discussions with the FDA on the Phase 3 Study Design in..
CI
2021DIMERIX : Experiences Delays in Approval of COVID-19 Trial in India
MT
2021Dimerix Limited Updates of DMX-200 Study in COVID-19 Patients in India
CI
2021DIMERIX : Recruits 24 Patients in Europe for COVID-19 Study;
MT
2021Dimerix Limited Advices COVID-19 Study Recruits Multiple Patients in Europe
CI
2021DIMERIX : Secures Nearly $4 Million Loan from Shareholder
MT
2021DIMERIX : Confirms Acceptable Feeding Tube Intake of DMX-200 Drug for COVID-19 Pneumonia P..
MT
2021Dimerix Limited Provides Update on the Collaboration with the REMAP-CAP Study into Pneu..
CI
2021Dimerix Limited Announces New Data Related to the Simultaneous Use of Dimerix' Lead Com..
CI
2021DIMERIX : Advances Clinical Studies of Drug Candidate DMX-200 for COVID-19 Patients
MT
2021Dimerix Limited Provides an Update on the Clarity 2.0 Study in Patients with COVID-19
CI
2021DIMERIX : Widens Net Loss in Fiscal First Half
MT
2021Dimerix Limited Plans for Next Study in Diabetic Kidney Disease
CI
2020DIMERIX : Starts Second COVID-19 Study for DMX-200; Shares Up 6%
MT
2020Dimerix Limited Announces Second International Study to Include DMX-200 in COVID-19 Pat..
CI
2020DIMERIX : Acute Respiratory Distress Syndrome in COVID-19 Patients Protocol Approved
MT
2020Dimerix Limited Announces Acute Respiratory Distress Syndrome in COVID-19 Patients Prot..
CI
2020Dimerix Limited Announces Positive Additional Data to Support DMX-200 Development
CI
2020Dimerix Limited Announces Additional Positive in Vitro Data to Support Further Developm..
CI
2020Dimerix Reports Positive Phase 2 Study Results of DMX-200 in Diabetic Kidney Disease
CI
2020Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2020
CI
2020DIMERIX : DMX-200 Posts Strong Results in Kidney Disease Trial
BU
2020DIMERIX’s DMX-200 Posts Strong Results in Kidney Disease Trial
CI
2020Dimerix Limited Announces Last Patient Completes Dosing in DKD Phase 2 Clinical Study
CI
2020Dimerix Limited Announces DMX-700 Program for Chronic Obstructive Pulmonary Disease Adv..
CI
2020Dimerix Limited Completes Last Patient Dosing in FSGS Phase 2 Clinical Study
CI
2020Dimerix Limited Announces Global REMAP-CAP Platform Trial Protocol To Include DMX-200
CI
2020Dimerix Limited Announces the Two Phase 2 Studies
CI
2020DMX-200 Treatment Continued Under TGA Special Access Scheme
CI
2020Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2019
CI
2020Dimerix Limited Announces DMX-200 Clinical Trial Update
CI
2019DIMERIX : Holds Pre-IND Meeting on DMX-200 With FDA
PU
2019Dimerix Limited Holds Pre-Ind Meeting on DMX-200 with FDA
CI
2019Dimerix Limited Announces the Resignation of David Franklyn as Non- Executive Director
CI
2019Dimerix Limited Announces New Drug Pipeline Candidate DMX-700
CI
2019Dimerix Limited Completes Enrolment for its Phase 2 Study of DMX-200
CI
2019Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2019
CI
2019Dimerix Limited Completes Enrollment of Patients for its Phase 2a Study of DMX-200
CI
2019Dimerix Limited Provides Clinical Update on DMX-200
CI
2019Dimerix Limited Signs Licence Agreement for Receptor-Hit Technology with Excellerate Bi..
CI
2019Dimerix Limited Updates on Activity Relating to the Commercial Scale Manufacturing of D..
CI
2019Dimerix Limited Reports Earnings Results for the Six Months Ended December 31, 2018; Pr..
CI
2018Dimerix Doses First Patient in DMX-200 Clinical Trial for Focal Segmental Glomeruloscle..
CI
2018Dimerix Limited Doses First Patient in DMX-200 Phase 2 Clinical Study
CI
2018Dimerix Limited Announces Registered Office Address Change
CI
2018Dimerix Limited Announces Consolidated Earnings Results for the Year Ended June 30, 201..
CI
2018Dimerix Limited Announces Management Changes
CI
2018Dimerix Limited Receives Ethics Approval for its DMX-200 Phase 2 Clinical Efficacy Tria..
CI
2018Dimerix Limited Announces Management Changes
CI
2018Dimerix Limited Appoints David Packham as Chief Medical Officer
CI
1  2Next
Upcoming event on DIMERIX LIMITED